New insider activity at Corcept Therapeutics ( (CORT) ) has taken place on November 26, 2025.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CDO William Guyer recently sold 4,500 shares of Corcept Therapeutics stock, amounting to a total transaction value of $364,050.
Recent Updates on CORT stock
Corcept Therapeutics has recently reported its Q3 2025 earnings, highlighting a 13.8% increase in revenue to $207.6 million, driven by significant growth in its hypercortisolism segment. However, the company faced a decline in net income, dropping to $19.7 million from $47.2 million the previous year, attributed to increased operating expenses and ongoing patent litigation with Teva Pharmaceuticals. The company is transitioning to a new pharmacy vendor to meet growing demand, which previously impacted financial results due to capacity constraints. Corcept’s oncology program is expanding, with new studies planned and significant clinical milestones anticipated for its drug relacorilant. Despite these advancements, the company’s stock experienced a decline, influenced by the unresolved patent litigation and the challenges in maintaining profitability. The company revised its 2025 revenue guidance to $800-$850 million, reflecting its strategic efforts to address these challenges and capitalize on growth opportunities.
Spark’s Take on CORT Stock
According to Spark, TipRanks’ AI Analyst, CORT is a Outperform.
Corcept Therapeutics’ overall stock score is driven by strong financial health and promising growth prospects in its pipeline, particularly in hypercortisolism and oncology. However, high valuation and declining net income pose risks. The technical indicators suggest neutral momentum, and unresolved patent litigation adds uncertainty.
To see Spark’s full report on CORT stock, click here.
More about Corcept Therapeutics
YTD Price Performance: 60.66%
Average Trading Volume: 822,503
Technical Sentiment Signal: Strong Buy
Current Market Cap: $8.44B